Cardiome Pharma (NASDAQ:CRME) Given “Buy” Rating at HC Wainwright

Cardiome Pharma (NASDAQ:CRME) (TSE:COM)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Wednesday, November 22nd. They currently have a $9.50 price target on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the stock. ValuEngine upgraded shares of Cardiome Pharma from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. Zacks Investment Research lowered shares of Cardiome Pharma from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Finally, Canaccord Genuity set a $8.00 target price on shares of Cardiome Pharma and gave the stock a “buy” rating in a report on Monday, August 21st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $5.31.

Cardiome Pharma (NASDAQ CRME) traded down $0.09 on Wednesday, reaching $1.50. 227,723 shares of the company traded hands, compared to its average volume of 111,291. Cardiome Pharma has a 52 week low of $1.29 and a 52 week high of $4.84. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.52 and a quick ratio of 4.71.

Cardiome Pharma (NASDAQ:CRME) (TSE:COM) last posted its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.04). Cardiome Pharma had a negative net margin of 112.91% and a negative return on equity of 94.68%. The company had revenue of $6.02 million for the quarter, compared to analysts’ expectations of $7.42 million. During the same period in the previous year, the business posted ($0.19) earnings per share. The business’s revenue was up 14.9% on a year-over-year basis. research analysts predict that Cardiome Pharma will post -0.84 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its holdings in Cardiome Pharma by 105.3% during the 1st quarter. JPMorgan Chase & Co. now owns 112,679 shares of the biopharmaceutical company’s stock valued at $339,000 after buying an additional 57,782 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Cardiome Pharma by 17.9% during the 1st quarter. Renaissance Technologies LLC now owns 253,413 shares of the biopharmaceutical company’s stock valued at $763,000 after buying an additional 38,400 shares in the last quarter. AlphaOne Investment Services LLC lifted its holdings in Cardiome Pharma by 14.9% during the 2nd quarter. AlphaOne Investment Services LLC now owns 632,739 shares of the biopharmaceutical company’s stock valued at $2,860,000 after buying an additional 82,027 shares in the last quarter. Stonepine Capital Management LLC lifted its holdings in Cardiome Pharma by 79.7% during the 3rd quarter. Stonepine Capital Management LLC now owns 2,866,785 shares of the biopharmaceutical company’s stock valued at $6,106,000 after buying an additional 1,271,236 shares in the last quarter. Finally, Westfield Capital Management Co. LP raised its holdings in shares of Cardiome Pharma by 8.0% in the 2nd quarter. Westfield Capital Management Co. LP now owns 5,286,340 shares of the biopharmaceutical company’s stock valued at $23,894,000 after purchasing an additional 391,392 shares in the last quarter. Institutional investors own 52.48% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Cardiome Pharma (NASDAQ:CRME) Given “Buy” Rating at HC Wainwright” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/11/cardiome-pharmas-crme-buy-rating-reaffirmed-at-hc-wainwright.html.

Cardiome Pharma Company Profile

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.

Receive News & Ratings for Cardiome Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply